Loading
Every dated change on the records linked to Clear cell renal cell carcinoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Sunitinib alone was non-inferior to cytoreductive nephrectomy plus sunitinib for overall survival in intermediate- and poor-risk metastatic clear cell renal cell carcinoma.
8-year OS HR 0.
A milestone in how this cancer is treated.
Nivolumab improved overall survival and response rate over everolimus in previously treated clear cell renal cell carcinoma; approved in November 2015.
A milestone in how this cancer is treated.